2.46
-0.22(-8.21%)
Currency In USD
| Previous Close | 2.68 |
| Open | 2.61 |
| Day High | 2.62 |
| Day Low | 2.44 |
| 52-Week High | 55.5 |
| 52-Week Low | 2.46 |
| Volume | 539,186 |
| Average Volume | 287,639 |
| Market Cap | 2.97M |
| PE | -0.05 |
| EPS | -49.75 |
| Moving Average 50 Days | 4.51 |
| Moving Average 200 Days | 12.03 |
| Change | -0.22 |
If you invested $1000 in Moleculin Biotech, Inc. (MBRX) since IPO date, it would be worth $0.14 as of February 21, 2026 at a share price of $2.46. Whereas If you bought $1000 worth of Moleculin Biotech, Inc. (MBRX) shares 5 years ago, it would be worth $1.33 as of February 21, 2026 at a share price of $2.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Moleculin Announces Exercise of Warrants for $8.3 Million Gross Proceeds
GlobeNewswire Inc.
Feb 19, 2026 1:39 PM GMT
HOUSTON, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced it has entered into agreements with certain holders of its existing warrants for the immediate exercise of certain ou
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
GlobeNewswire Inc.
Feb 18, 2026 1:20 PM GMT
Preliminary blinded CR rate showed 67% improvement over historical cytarabine response Roughly 35% of the subjects treated to date represent ventoclax regimen failuresFirst 45 subjects treated on track for Q1 2026 milestone with unblinding thereafter
Moleculin Announces Notice of Allowance for Japanese Patent Covering Annamycin
GlobeNewswire Inc.
Feb 17, 2026 1:35 PM GMT
HOUSTON, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that the Japan Patent Office (JPO) has issued a notice of allowance for Patent Application No. 2021-577862 titled, “M